Jason Burrus, MD
Urology · Homewood, ALNPI 1619935178
Payments from drug & device makers
Across 197 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- Antares Pharma, Inc.$608
- Procept Biorobotics Corporation$529
- Sumitomo Pharma America, Inc.$471
- Pfizer$316
- Astellas Pharma US Inc$229
- plus $2K from 34 others
What the payments were for
- Travel & lodging$1,03020%
- Food & beverage$3,89575%
- Education$2795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 8 | $1,133 |
| Antares Pharma, Inc. | 34 | $608 |
| Procept Biorobotics Corporation | 8 | $529 |
| Sumitomo Pharma America, Inc. | 28 | $471 |
| Pfizer | 16 | $316 |
| Astellas Pharma US Inc | 9 | $229 |
| AbbVie(2 entities) | 4 | $165 |
| Coloplast | 7 | $145 |
| Urovant Sciences Inc | 8 | $144 |
| Urogen Pharma, Inc. | 7 | $133 |
| Verity Pharmaceuticals Inc. | 6 | $124 |
| Myovant Sciences Inc. | 7 | $112 |
| Bayer | 5 | $101 |
| Immunitybio, Inc. | 3 | $97 |
| Progenics Pharmaceuticals, Inc. | 4 | $83 |
| Tolmar, Inc. | 3 | $76 |
| Myriad Genetic Laboratories, Inc. | 3 | $70 |
| Endo Pharmaceuticals Inc. | 3 | $64 |
| Olympus America Inc. | 2 | $59 |
| Merck | 2 | $49 |
| Halozyme Inc | 2 | $44 |
| Convatec Inc. | 2 | $43 |
| Axonics, Inc. | 2 | $33 |
| Hollister Incorporated | 2 | $32 |
| Medtronic | 2 | $32 |
| Johnson & Johnson | 2 | $32 |
| Mission Pharmacal Company | 2 | $31 |
| 180 Medical, Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Photocure Inc | 2 | $25 |
| Rochester Medical Corporation | 1 | $23 |
| Pharmaand GmbH | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Cook Medical LLC | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Bard Access Systems, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$873
- AQUABEAM SYSTEM$265
How this compares
$5,205 in reported general payments places this provider in the 55th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 111 | $89,467 |
| GemtesaVibegron | 119 | $71,854 |
| OrgovyxRelugolix | 18 | $48,400 |
| Testosterone | 65 | $12,613 |
| XyostedTestosterone Enanthate | 20 | $12,075 |
| Tamsulosin Hcl | 632 | $10,027 |
| Finasteride | 320 | $4,515 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 123 | $2,194 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,038 |
| Methenamine Hippurate | 30 | $1,318 |
| Dutasteride | 23 | $1,247 |
| Testosterone Cypionate | 52 | $1,232 |
| Cephalexin | 76 | $1,129 |
| Solifenacin Succinate | 14 | $970 |
| Ciprofloxacin Hcl | 190 | $951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $471 | $120,254137 claims |
| Astellas Pharma US IncMyrbetriq | $229 | $89,467111 claims |
| Antares Pharma, Inc.Xyosted | $608 | $12,07520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 179 urology providers in Alabama.
Other urology in Homewood
- Vincent BivinsHomewood$1.3M
- Charles BuggHomewood$544K
- Brian ChristineHomewood$372K
- Austin LutzHomewood$367K
- Mark DeguentherHomewood$342K
- Paula RookisHomewood$174K
- Bryant PooleHomewood$123K
- Andrew StrangHomewood$91K
- Michael BrewerHomewood$77K
- Rachel EngelbergHomewood$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.